Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR33532754

— · D

259f9b76-f097-5c20-bfe7-1005a6290cb2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
D
subtype
D

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
  • ANGIOGENESIS+0.520
  • HEDGEHOG_SIGNALING+0.470
  • APICAL_SURFACE+0.430
  • MYOGENESIS+0.420
  • COAGULATION+0.410
  • APICAL_JUNCTION+0.370
  • NOTCH_SIGNALING+0.320
  • PANCREAS_BETA_CELLS+0.310
  • TNFA_SIGNALING_VIA_NFKB+0.260

Top 10 suppressed

  • MYC_TARGETS_V1-0.470
  • E2F_TARGETS-0.370
  • G2M_CHECKPOINT-0.370
  • PI3K_AKT_MTOR_SIGNALING-0.360
  • MTORC1_SIGNALING-0.350
  • OXIDATIVE_PHOSPHORYLATION-0.330
  • PROTEIN_SECRETION-0.260
  • MYC_TARGETS_V2-0.230
  • SPERMATOGENESIS-0.200
  • FATTY_ACID_METABOLISM-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120050037.TNBC
breast-umap@18
—C0.907
2TCGA-AC-A23G-01A-11R-A213-07
breast-umap@18
—A0.889
357583139-d2d3-4b97-a616-aa96058d4682
melanoma-umap@29
——0.886
469d9a82b-5c37-45bd-a1cf-ffe1392e84fc
melanoma-umap@29
——0.884
5MNG128
mng-umap@100
——0.878
6ERR2208910
melanoma-umap@29
——0.865
7TCGA-E2-A153-01A-12R-A12D-07
breast-umap@18
—A0.856
8TCGA-OL-A6VQ-01A-12R-A41B-07
breast-umap@18
—A0.855
9C3N-02339
lung-landscapes@6
—cohortSQ10.855
10d1ecfbcd-8e13-4c5c-8536-6fb1e878e193
melanoma-umap@29
——0.855

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.550Inavolisib— uncovered
ANGIOGENESIS0.520Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.470Inavolisib— uncovered
APICAL_SURFACE0.430Temsirolimus— uncovered
MYOGENESIS0.420Inavolisib— uncovered
COAGULATION0.410Binimetinib— uncovered
APICAL_JUNCTION0.370Inavolisib— uncovered
NOTCH_SIGNALING0.320Inavolisib— uncovered
PANCREAS_BETA_CELLS0.310Cobimetinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.260Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.260Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.240Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.210Inavolisib— uncovered
KRAS_SIGNALING_DN0.200Remibrutinib— uncovered
TGF_BETA_SIGNALING0.190Inavolisib— uncovered
P53_PATHWAY0.180Idelalisib— uncovered
HYPOXIA0.170Idelalisib— uncovered
UV_RESPONSE_UP0.170Idelalisib— uncovered
APOPTOSIS0.150Idelalisib— uncovered
KRAS_SIGNALING_UP0.140Inavolisib— uncovered